PharVision Advisers’s PTC PTC Stock Holding History

PharVision Advisers’s Portfolio PTC Stock Details PTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,273	Closed	-$258K	–	944
2025 Q3	$258K	Buy	+1,273	New	+$260K	0.15%	314

Other funds holding PTC

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Eagle Capital Management (New York) New York $32.7B AUM 17.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PharVision Advisers's PTC Position: Q4 2025 in Review

PharVision Advisers sold out of PTC (PTC) in Q4 2025, closing a stake of 1,273 shares — an estimated $258K sold.

PharVision Advisers first reported a position in PTC in Q3 2025 and held it in 1 quarter. The position peaked at $258K in Q3 2025. 723 funds tracked by Wall St. Rank hold PTC as of Q4 2025.

PharVision Advisers reported no remaining PTC position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 1,273 PTC shares in Q4 2025, an estimated $258K.
PharVision Advisers first reported a position in PTC in Q3 2025 and held it in 1 quarter.
PharVision Advisers's PTC position peaked at $258K in Q3 2025.
723 funds tracked by Wall St. Rank held PTC as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.